Danaher (DHR) said late Thursday it is collaborating with AstraZeneca (AZN) to scale precision medicine, including developing AI-powered diagnostics.
The partnership would create a framework for diagnostics research, development and commercialization, Danaher said, adding that it will support the development cycle through its Centers for Enabling Precision Medicine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.